Boston Scientific (NYSE:BSX) Upgraded at Wall Street Zen

Posted by Geri Gentry on Jul 28th, 2026

Wall Street Zen upgraded shares of Boston Scientific (NYSE:BSX – Free Report) from a hold rating to a buy rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on BSX. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research report on Thursday, May 28th. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Bank of America reduced their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Canaccord Genuity Group decreased their target price on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $79.64.

Read Our Latest Stock Analysis on Boston Scientific

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $45.56 on Friday. The company’s 50 day simple moving average is $47.00 and its 200 day simple moving average is $63.47. The stock has a market capitalization of $67.72 billion, a price-to-earnings ratio of 19.06, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific has a 1 year low of $42.20 and a 1 year high of $109.50.

Boston Scientific announced that its board has authorized a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 9,800 shares of company stock worth $554,012. Corporate insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of BSX. Brighton Jones LLC increased its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC grew its holdings in Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares during the last quarter. Ieq Capital LLC grew its holdings in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after acquiring an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.